AOD-9604

AOD-9604 (Anti-Obesity Drug 9604) is a 16-amino acid synthetic peptide corresponding to the C-terminal region of human growth hormone (hGH), specifically amino acids 176–191. It was developed by Metabolic Pharmaceuticals Ltd (Australia) as part of a program to isolate GH's fat-burning properties from its other biological activities.

The rationale for developing AOD-9604 was based on research showing that the 176–191 fragment of GH retained the lipid-metabolizing (lipolytic) properties of the full protein while lacking the ability to stimulate IGF-1 production or affect glucose/insulin metabolism. This separation of activities is pharmacologically significant: the primary safety concerns with using GH for weight management are insulin resistance and IGF-1 elevation. AOD-9604 theoretically avoids both.

AOD-9604 received "Generally Recognized As Safe" (GRAS) status from the US FDA for use as a food ingredient, which is a limited regulatory recognition but is notable — it means the FDA has reviewed some safety data for this compound. However, GRAS status as a food ingredient is very different from drug approval for medical use. Metabolic Pharmaceuticals' clinical trials for obesity treatment ultimately did not meet primary endpoints, and the compound was not approved as an obesity drug.

AOD-9604 continues to be studied and used in research contexts for fat loss and is also being investigated for cartilage repair — an unexpected finding that has attracted new research interest.

AOD-9604 acts on fat tissue through GH receptor-like mechanisms:

• Lipolysis stimulation: AOD-9604 stimulates breakdown of triglycerides in adipocytes (fat cells) through activation of hormone-sensitive lipase (HSL), releasing free fatty acids for energy use. This mimics GH's acute lipolytic effect without GH's systemic hormone-like actions.
• Lipogenesis inhibition: The peptide inhibits de novo lipogenesis (formation of new fat from carbohydrates and proteins), reducing fat accumulation alongside promoting fat breakdown.
• Beta-3 adrenergic receptor activation: Research suggests AOD-9604 may activate beta-3 adrenergic receptors on adipocytes, which are the primary targets of catecholamines for fat burning.
• No IGF-1 stimulation: Unlike full GH, AOD-9604 does not activate insulin-like growth factor 1 (IGF-1) production, eliminating one of the primary growth and tumor-related concerns of GH therapy.
• No glucose/insulin effects: Clinical studies confirmed AOD-9604 does not significantly affect blood glucose or insulin levels — a key advantage over full GH for metabolically at-risk populations.
• Cartilage regeneration: Studies (primarily in vitro and animal models) suggest AOD-9604 may have activity in cartilage repair and regeneration, potentially through effects on chondrocyte proliferation.

AOD-9604's potential benefits center on metabolic and body composition effects:

• Targeted fat loss: Animal studies demonstrated significant reduction in body fat without the metabolic side effects of full GH. Obese rodent models treated with AOD-9604 show fat mass reduction comparable to full GH but without IGF-1 elevation.
• Metabolic safety profile: The absence of significant glucose, insulin, or IGF-1 effects makes AOD-9604 theoretically safer for use in overweight and obese individuals who may already have insulin resistance, compared to full GH.
• Muscle preservation: Animal data suggests that fat loss with AOD-9604 is preferentially from fat tissue rather than lean tissue — a favorable body recomposition profile.
• Cartilage repair (emerging): In vitro and early animal research shows potential for cartilage regeneration, particularly relevant to osteoarthritis. A clinical trial in knee osteoarthritis was conducted by Paradigm Biopharmaceuticals using AOD-9604 as an intra-articular injection.

AOD-9604 has a favorable safety profile supported by clinical trial data:

• FDA GRAS status: The compound received GRAS status as a food ingredient, reflecting some regulatory safety evaluation, though this is not equivalent to drug safety approval
• Clinical trial tolerability: Phase I and Phase II clinical trials conducted by Metabolic Pharmaceuticals generally found AOD-9604 well-tolerated at studied doses
• Injection site reactions: Minor discomfort with subcutaneous administration
• Headache and nausea: Reported in some clinical trial subjects
• No significant metabolic effects: Blood glucose, insulin, HbA1c, and IGF-1 were not significantly altered in clinical studies, which distinguishes it favorably from full GH

Long-term safety data for subcutaneous use in the research community context (typically higher and more frequent dosing than clinical trials) is limited. The GRAS status applies to food ingredient use, not to injectable research doses.

Disclaimer: AOD-9604 is not FDA-approved for medical use. The following is for educational purposes only.

Dosing from clinical trials and research protocols:

• Clinical trial oral dose: Metabolic Pharmaceuticals' Phase II trials used oral doses of 1–30 mg/day; the optimal dose was around 1–9 mg/day in early studies
• Subcutaneous injection (research community): 250–500 mcg per day, typically once daily in the morning (fasted state preferred)
• Timing: Administration in a fasted state maximizes lipolytic response; insulin levels should be low for optimal fat-mobilizing effect
• Intra-articular (cartilage research): Paradigm Biopharmaceuticals' clinical trials used injections directly into affected joints at specific doses for osteoarthritis applications

AOD-9604 research spans obesity and, more recently, joint health:

• Metabolic Pharmaceuticals obesity trials: A Phase IIb trial (PROOF study) tested AOD-9604 at doses of 1–30 mg/day orally in obese adults. While early studies showed fat loss at certain doses, the Phase IIb trial did not meet its primary endpoint of statistically significant superior weight loss versus placebo in the full study population. This led to abandonment of the obesity drug development program.
• Animal fat loss studies: Rodent studies consistently demonstrated significant fat mass reduction with AOD-9604 versus controls, providing mechanistic validation and a basis for continued interest despite the clinical trial results.
• Paradigm Biopharmaceuticals (cartilage): An Australian company, Paradigm Biopharmaceuticals, has advanced AOD-9604 into clinical trials for knee osteoarthritis as an intra-articular injection, representing a significant pivot from weight management to joint health. Phase II results showed positive pain reduction signals.

The failure to meet obesity drug endpoints illustrates the challenge of translating animal fat loss data to human weight management — a space where many compounds with animal efficacy have failed in Phase III trials.